What is the primary reason for the significant net loss reported in this quarter?

The significant net loss of $309 million for the quarter and $292 million year-to-date is primarily due to substantial non-recurring charges. These include a $291 million impairment charge related to the planned sale of the perfusion products business and another $45 million charge for discontinuing certain products and impairing associated goodwill and intangibles. Additionally, $18 million in non-recurring spin-off expenses were incurred.

How has the company's net sales performance changed since becoming an independent entity?

Net sales have declined year-over-year. For the three months ended June 30, 2000, net sales decreased by 12.0% to $205 million, and for the six months ended June 30, 2000, they decreased by 5.1% to $431 million. This decline was influenced by a change in the accounting for its Japanese operations and weaker performance in the vascular and perfusion product lines, partially offset by growth in cardiac surgery.

What is the company's current liquidity situation?

As of June 30, 2000, the company had $2 million in cash and cash equivalents. It has drawn down $531 million of its $650 million revolving credit facilities to manage working capital and finance asset transfers post-spin-off. While management believes it has sufficient financial flexibility, investors should note the significant debt utilization and limited cash on hand.

EW 10-Q Quarterly Report Q2 FY2000 — Revenue, Net Income, EPS

Q: What are the company's key strategic moves discussed in this report?

The company is actively reshaping its portfolio. It has entered into an agreement to sell the majority of its perfusion products business and has already completed the sale of its mechanical cardiac assist product line, recognizing a gain. Management is focusing on its core cardiac surgery and critical care segments and continuing research and development for new products.

Summary

Edwards Lifesciences Corporation (EW) reported its financial results for the second quarter and first six months of 2000, marking its first reporting period as an independent, publicly traded company following its spin-off from Baxter International Inc. on March 31, 2000. The company experienced a significant net loss in the quarter and year-to-date, largely driven by substantial non-recurring charges related to asset disposals and restructuring. Net sales declined year-over-year, impacted by a change in accounting for Japanese operations and a general slowdown in certain product lines like vascular and perfusion. Despite the top-line pressures and the significant net loss, the company is strategically divesting from its perfusion products business and has gained $35 million from the sale of its mechanical cardiac assist product line. The company is also investing in its core cardiac surgery and critical care segments, with positive growth noted in cardiac surgery. Investors should monitor the impact of these strategic divestitures and the company's ability to return to profitability, alongside ongoing litigation and product development efforts.

Key Highlights

1Reported a net loss of $309 million for the three months ended June 30, 2000, and a year-to-date net loss of $292 million, significantly impacted by non-recurring charges.
2Total net sales decreased by 12.0% to $205 million for the three months ended June 30, 2000, and by 5.1% to $431 million for the six months ended June 30, 2000, compared to the prior year periods.
3Recorded significant non-recurring charges totaling $301 million in the second quarter, primarily related to the impairment of assets for the planned sale of the perfusion products business ($291 million) and other product portfolio adjustments.
4Completed the sale of its mechanical cardiac assist product line, recognizing a pre-tax gain of $35 million.
5Initiated strategic divestiture of the majority of its U.S. and Western European perfusion products business.
6Cardiac surgery product sales showed modest growth of 1.3% and 2.6% for the three and six-month periods, respectively, indicating resilience in a key segment.
7The company's cash position decreased, with cash and cash equivalents at $2 million as of June 30, 2000, down from $0 at the beginning of the period, while utilizing significant portions of its revolving credit facilities.

Edwards Lifesciences Corp Quarterly Report for Q2 Ended Jun 30, 2000

Summary

Key Highlights

Frequently Asked Questions